Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
ATLANTA, Feb. 27, 2018 -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will present at the 38th Annual Cowen & Co. Health Care Conference to be held March 12-14, 2018 at the Boston Marriott Copley Place, Boston, Massachusetts. Alimera’s presentation will take place Tuesday, March 13 at 12:00PM.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of Alimera's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
For press inquiries:
Katie Brazel
for Alimera Sciences
404-317-8361
[email protected]
For investor inquiries:
CG Capital
for Alimera Sciences
877-889-1972
[email protected]
